Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 62

Results For "technologies"

1078 News Found

Quantumzyme and BEC Chemicals to collaborate for green chemistry development
News | January 14, 2023

Quantumzyme and BEC Chemicals to collaborate for green chemistry development

This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.


135 crore footfalls registered at AB-HWCs
Policy | January 13, 2023

135 crore footfalls registered at AB-HWCs

Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs


Apollo Genomics Institutes launched at Apollo Hospitals Navi Mumbai
News | January 12, 2023

Apollo Genomics Institutes launched at Apollo Hospitals Navi Mumbai

Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders


Moderna to acquire Oriciro Genomics
News | January 11, 2023

Moderna to acquire Oriciro Genomics

OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines


Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
News | January 11, 2023

Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics

Collaboration to generate and develop therapeutics for oncology and non-oncology conditions


ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology
News | January 10, 2023

ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology

The new project further expands the partner's long-term collaboration on new technologies for R&D


World's first intranasal vaccine iNCOVACC will be rolled out in the fourth week of January
News | December 29, 2022

World's first intranasal vaccine iNCOVACC will be rolled out in the fourth week of January

The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics